TNFRSF4 and diffuse large B-cell lymphoma: In this regard, our group previously reported the depletion of MDSCs, Tregs and inhibitory PD-1+OX40− T cells, as well as the increase in activated OX40+PD-1− T cells in R/R DLBCL patients with OS > 24 months from the R2-GDP-GOTEL trial [26].